Bellicum reports inducement grants under nasdaq listing rule 5635(c)(4)

Houston, may 02, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 3 new employees consisting of an aggregate of 33,000 stock options. the compensation committee of the board of directors approved the grants with an effective date of april 30, 2022. the stock options were granted as inducements material to the employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
BLCM Ratings Summary
BLCM Quant Ranking